annb0t
Top 20
SYDNEY, March 29, 2022--(BUSINESS WIRE)--Australian biotech company Noxopharm (ASX:NOX) has announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to Veyonda®, its lead oncology drug candidate, for use in the treatment of soft tissue sarcoma.
The ODD program was established by the FDA to encourage development of safe and effective treatments of rare diseases and disorders that affect fewer than 200,000 people in the U.S. annually. Soft tissue sarcomas are...
>>> Read more: FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment
The ODD program was established by the FDA to encourage development of safe and effective treatments of rare diseases and disorders that affect fewer than 200,000 people in the U.S. annually. Soft tissue sarcomas are...
>>> Read more: FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment
